Selective dopamine D2 receptor agonist (Ki values are 4.8, ~24, ~30 and 1900 nM at D2, D3, D4 and D1 receptors respectively).
Sold with the permission of Eli Lilly and Company
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 255.79. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.91 mL||19.55 mL||39.09 mL|
|5 mM||0.78 mL||3.91 mL||7.82 mL|
|10 mM||0.39 mL||1.95 mL||3.91 mL|
|50 mM||0.08 mL||0.39 mL||0.78 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Levant et al (1996) Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J.Pharmacol.Exp.Ther. 278 145 PMID: 8764345
Seeman and Van Tol (1994) Dopamine receptor pharmacology. Trends Pharmacol.Sci. 15 264 PMID: 7940991
Sullivan et al (1998) Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience 83 781 PMID: 9483561
If you know of a relevant reference for (-)-Quinpirole hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Selective D2-like agonists Dopamine Non-Selective Receptors dopaminergic Non-selective Dopamine
21 Citations for (-)-Quinpirole hydrochloride
Citations are publications that use Tocris products. Selected citations for (-)-Quinpirole hydrochloride include:
Borgs et al (2016) Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects. Scientific Reports 6 33377 PMID: 27640816
Picton et al (2016) Mechanisms underlying the endogenous dopaminergic inhibition of spinal locomotor circuit function in Xenopus tadpoles. Scientific Reports 6 35749 PMID: 27760989
Tozzi et al (2015) Endogenous 17β-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. Front Cell Neurosci 9 192 PMID: 26074768
Wang et al (2015) A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation. Proc Natl Acad Sci U S A 11 2057 PMID: 26649942
Shin et al (2015) Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Nat Neurosci 112 8124 PMID: 26080439
Xing et al (2015) Dopamine D1 receptor activation regulates the expression of the estrogen synthesis gene aromatase B in radial glial cells. Neuropsychopharmacology 9 310 PMID: 26388722
Ahmadiantehrani and Ron (2013) Dopamine D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gβγ-Erk1/2-dependent induction of Zif268. J Neurochem PMID: 23373701
Hutchinson et al (2012) Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin. Eur J Neurosci 37 321 PMID: 21956448
Hook et al (2012) Dopaminergic modulation of ganglion-cell photoreceptors in rat. Autophagy 35 507 PMID: 22304466
Ferraro et al (2012) A novel mechanism of cocaine to enhance dopamine d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. J Neurosci 37 1856 PMID: 22453136
Gantz et al (2011) Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. J Neurosci 31 12629 PMID: 21880923
Yoon et al (2011) Wnt5a-dopamine D2 receptor interactions regulate dopamine neuron development via extracellular signal-regulated kinase (ERK) activation. Neuropsychopharmacology 286 15641 PMID: 21454669
Burgess et al (2010) Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 1295 PMID: 21061851
Higley and Sabatini (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13 958 PMID: 20601948
Deng et al (2010) MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. J Biol Chem 13 1128 PMID: 20711186
Goffin et al (2010) Dopamine-dependent tuning of striatal inhibitory synaptogenesis. Neuron 30 2935 PMID: 20181591
Chuhma et al (2009) Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 164 1068 PMID: 19729052
Zapata et al (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282 35842 PMID: 17923483
Kitada et al (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104 11441 PMID: 17563363
González-Maeso et al (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. PLoS One 53 439 PMID: 17270739
Marchese et al (2003) Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 140 520 PMID: 12970091
Do you know of a great paper that uses (-)-Quinpirole hydrochloride from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.